Solventum (SOLV) Fiscal Q2 EPS Jumps 8%
Solventum (NYSE:SOLV), the health technology company known for medical devices and digital health solutions, reported its earnings for the second quarter of fiscal 2025 on August 7, 2025. The company posted revenue and adjusted earnings per share that exceeded analyst expectations. Revenue (GAAP) reached $2.161 billion (analyst estimate: $2.119 billion) for Q2 2025, while adjusted earnings per share came in at $1.69 (estimate: $1.45) for Q2 2025. Management raised both full-year organic sales growth and adjusted EPS guidance for FY2025. Increased operating expenses, and noted risks from tariffs that are expected to pressure profitability in the coming months. Overall, the quarter provided evidence of business progress but also surfaced areas for investor scrutiny, especially around cash conversion and future cost management.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Solventum is a large healthcare company focused on medical devices, dental products, and digital health solutions. Its business includes the design, production, and marketing of items such as advanced wound care products, surgical solutions, dental materials, revenue cycle management software, and filtration systems. The company employs close to 22,000 people worldwide and allocates significant resources to research and development through a team of scientists, engineers, and clinical staff. This innovation-focused approach enables the company to serve hospitals, clinics, dental offices, and other care providers around the globe.
Source Fool.com
